Proteomic Profiling Service

Proteomic profiling is a comprehensive technology for studying the composition, abundance, and post-translational modifications of proteins in biological samples. Using mass spectrometry (MS) and high-throughput platforms, proteomic profiling reveals dynamic changes in proteins within complex biological systems, providing deep molecular-level insights. The process involves protein extraction and digestion, peptide separation by liquid chromatography, protein detection via mass spectrometry, and data analysis through bioinformatics tools to generate protein expression profiles and pathway analyses.

MtoZ Biolabs-Proteomic Profiling Service1

Figure 1. The Workflow of Proteomic Profiling

Proteomic profiling addresses questions that genomics or transcriptomics cannot answer. It enables the discovery of disease-related biomarkers, such as exosome-specific proteins in myocardial infarction, and uncovers resistance mechanisms in cancer, such as CDK6-driven resistance in multiple myeloma. Additionally, it supports target identification, validation, and therapy safety evaluation in drug development. By decoding complex protein networks, this technology provides powerful support for disease mechanism research, precision medicine, and drug discovery.

MtoZ Biolabs offers professional proteomic profiling service utilizing advanced mass spectrometry platforms (such as Thermo Fisher Orbitrap series) and efficient liquid chromatography systems. Backed by extensive project experience and a highly skilled bioinformatics team, we deliver precise analysis of protein composition, abundance, and post-translational modifications. Our comprehensive proteomic profiling service, from sample preparation to in-depth data analysis, ensures high-quality proteomic data to support disease mechanism research, biomarker discovery, and drug development. If you are interested in our service, please feel free to contact us.

Service Advantages

1. Advanced Technology and High Sensitivity

MtoZ Biolabs' Proteomic Profiling Service utilizes state-of-the-art mass spectrometry platforms, such as the Thermo Fisher Orbitrap series, ensuring high sensitivity and accuracy in detecting low-abundance proteins and post-translational modifications.

2. Comprehensive Data Analysis

Our Proteomic Profiling Service is supported by an expert bioinformatics team that provides in-depth data analysis, including differential protein expression, pathway mapping, and protein-protein interaction networks, delivering actionable insights for complex biological questions.

3. Customized Solutions and Expertise

With extensive project experience, MtoZ Biolabs' Proteomic Profiling Service offers tailored workflows to meet diverse research needs, addressing challenges such as sample complexity, quantification accuracy, and large-scale data interpretation.

Case Study

1. Proteomic Profiling of Extracellular Vesicles Reveals Additional Diagnostic Biomarkers for Myocardial Infarction Compared to Plasma Alone

This study investigated whether extracellular vesicles (EVs) from plasma offer additional diagnostic insights for myocardial infarction (MI) compared to plasma alone. Using proximity extension assays, 11 dysregulated proteins were identified in EVs from MI patients, three of which—CTRC, SRC, and CCL17—were unaltered in plasma and lacked prior evidence as MI biomarkers. EV-associated SRC levels were further validated in patients with coronary artery disease. These findings demonstrate that EV analysis provides unique diagnostic information beyond plasma proteomics. Proteomic profiling service enables comprehensive analysis of EV-associated proteins, offering insights for disease diagnosis and biomarker discovery.

MtoZ Biolabs-Proteomic Profiling Service2

Gidlöf, O. et al. Sci Rep. 2019.

Figure 2. Proteomic Profiling of EV Lysates and Plasma

2. Proteomic Profiling Reveals CDK6 Upregulation as a Targetable Resistance Mechanism for lenalidomide in Multiple Myeloma

This study identifies CDK6 upregulation as a non-genetic resistance mechanism to lenalidomide in multiple myeloma. Using TMT-based proteomic and phosphoproteomic analyses along with RNA sequencing, a CDK6-driven resistance signature, including TRIP13 and RRM1, was found in pre-treatment and relapse patient samples. CDK6 overexpression reduced IMiD sensitivity, while CDK6 inhibition or degradation synergized with IMiDs in vitro and in vivo, providing a potential therapeutic strategy for IMiD-resistant multiple myeloma. Proteomic profiling service enables the discovery of resistance-related protein signatures and therapeutic targets through advanced proteomic and phosphoproteomic analyses.

MtoZ Biolabs-Proteomic Profiling Service3

Ng, YLD. et al. Nat Commun. 2022.

Figure 3. Identification of CDK6 Protein Upregulation in Relapsed Multiple Myeloma Patients

Applications

1. Proteomic Profiling is Applied in Biomarker Discovery

The proteome encompasses the complete set of proteins produced by cells in an organism. Advances in aptamer- and antibody-based technologies have enabled high-throughput protein profiling for biomarker discovery in various diseases. Platforms such as Olink® and Somascan® use innovative approaches to quantify protein abundance. Olink employs a dual-recognition immunoassay with DNA oligonucleotides that form a unique barcode upon protein binding, while Somascan uses SOMAmer reagents to bind proteins and quantify them via fluorescence on a microarray. Olink offers higher specificity and phenotypic associations, whereas Soma provides greater precision and proteome coverage. Proteomic profiling service applies advanced high-throughput platforms to support comprehensive protein analysis and biomarker identification across diverse biological conditions.

MtoZ Biolabs-Proteomic Profiling Service4

Truby, LK. et al. Curr Heart Fail Rep. 2023.

Figure 4. Proteomic Profiling for Biomarker Discovery

2. Proteomic Profiling is Applied in in the Preclinical Drug Discovery Process

Mass spectrometry-based proteomics is applied across various stages of drug discovery, including target identification, target validation, lead compound screening, mechanism of action studies, and toxicity assessment. By analyzing protein expression, dynamics, and post-translational modifications, mass spectrometry supports multiple critical steps in drug development. Proteomic profiling service utilizes mass spectrometry platforms to cover multiple stages, from target discovery to mechanism research, providing comprehensive proteomic data support.

MtoZ Biolabs-Proteomic Profiling Service5